Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Lindeman

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibDavid M Jackman, Beow Y Yeap, Lecia V Sequist, et al.
Cell Reports. Medicine|October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironmentJames R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Science (New York, N.Y.)|May 1, 2004
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyJ Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, et al.
Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.
Archives of Pathology & Laboratory Medicine|March 6, 2018
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint ReviewJason D Merker, Geoffrey R Oxnard, Carolyn Compton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2018
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint ReviewJason D Merker, Geoffrey R Oxnard, Carolyn Compton, et al.
Genome Medicine|July 28, 2016
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicineAndrea Garofalo, Lynette Sholl, Brendan Reardon, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerJussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibDavid M Jackman, Beow Y Yeap, Lecia V Sequist, et al.
Cell Reports. Medicine|October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironmentJames R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Science (New York, N.Y.)|May 1, 2004
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyJ Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, et al.
Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.
Archives of Pathology & Laboratory Medicine|March 6, 2018
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint ReviewJason D Merker, Geoffrey R Oxnard, Carolyn Compton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2018
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint ReviewJason D Merker, Geoffrey R Oxnard, Carolyn Compton, et al.
Genome Medicine|July 28, 2016
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicineAndrea Garofalo, Lynette Sholl, Brendan Reardon, et al.
Neuro-Oncology|April 17, 2025
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerJussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, et al.
Pageof 7